Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. The ultimate objective is to establish the diagnostic efficacy of this approach through clinical validation, providing clinicians with a novel diagnostic tool capable of significantly reducing unnecessary prostate biopsy procedures.

NCT Number	NCT07238959
Lead Sponsor	Shanghai Changzheng Hospital Collaborators: West China Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Ningbo University, Jiangsu Provincial People's Hospital, The First Affiliated Hospital of Soochow University
Conditions	Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm
Enrollment	1,100 participants
Start Date	2025-12
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-11-20